Journal of Neurology

, Volume 257, Supplement 2, pp 249–252 | Cite as

A brief history of levodopa

  • Oleh Hornykiewicz
Article

Abstract

This article highlights some landmarks in the history of levodopa, beginning with its isolation in 1910–13 from seedlings of Vicia faba to the demonstration, in 1961, of its “miraculous” effect in patients with Parkinson’s disease (PD). Midway between these two time points, in 1938, l-dopa decarboxylase was discovered, the enzyme that produces dopamine (DA) from levodopa. In 1957, DA was shown to occur in the brain, and in 1959 it was found to be enriched in the basal ganglia. At that time the striatal localization of DA, together with studies done in 1957–58 in naive and reserpine-treated animals regarding DA in the brain and the central effects of levodopa, suggested its possible involvement in “extrapyramidal control” and “reserpine parkinsonism”. Following these discoveries, a study of (postmortem) brains of patients with basal ganglia disorders, including PD, was started, demonstrating, in 1960, a severe striatal DA deficit specifically in PD, thus furnishing a rational basis for the concept of “DA replacement therapy” with levodopa. Accordingly, in 1961, the first highly successful clinical trial with i.v. levodopa was carried out. In 1963, the DA deficit in the PD substantia nigra was found, indicative of a nigrostriatal DA pathway in the human brain, subsequently established in animal studies in 1964–65. In 1967, the chronic, high dose oral levodopa regimen was introduced in treatment of PD. Besides the above highlights in the history of levodopa, the article also cites critical opinions of world authorities in brain research of the time, harmful to the cause of DA, levodopa and PD. Today, the concept of DA replacement with levodopa is uncontested, with levodopa being the “gold standard” of modern drug treatment of PD.

Keywords

History of Parkinson’s disease Levodopa therapy Striatal and nigral dopamine deficit 

Notes

Conflicts of interest

None.

References

  1. 1.
    Torquati T (1913) Sulla presenza di una sostanza azotata nei germogli del semi di “vicia faba”. Arch Farmacol sper 15:213–223Google Scholar
  2. 2.
    Guggenheirn M (1913) Dioxyphenylalanin, eine neue Aminosäure ausVicia faba. Hoppe-Seyler’s Z Physiol Chem 88:276–284Google Scholar
  3. 3.
    Holtz P (1939) Dopadecarboxylase. Naturwissenschaften 27:724–725CrossRefGoogle Scholar
  4. 4.
    Blaschko H (1939) The specific action of l-dopa decarboxylase. J Physiol 96:50P–51PGoogle Scholar
  5. 5.
    Holtz P, Heise R, Lüdke K (1938) Fermentativer Abbau von l-Dioxyphenylalanin durch die Niere. Arch Exp Path Pharmak 191:87–118CrossRefGoogle Scholar
  6. 6.
    Hornykiewicz O (2002) l-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23:65–70PubMedCrossRefGoogle Scholar
  7. 7.
    Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180:244–245PubMedCrossRefGoogle Scholar
  8. 8.
    Weil-Malherbe H, Bone AD (1957) Intracellular distribution of catecholamines in the brain. Nature 180:1050–1051PubMedCrossRefGoogle Scholar
  9. 9.
    Holtz P, Balzer H, Westermann E, Wezler E (1957) Beeinflussung der Evipannarkose durch Reserpin, Iproniazid und biogene Amine. Arch Exp Path Pharmak 131:333–348Google Scholar
  10. 10.
    Carlsson A, Lindqvist M, Magnusson T (1957) 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptamine as reserpine antagonists. Nature 127:471Google Scholar
  11. 11.
    Pletscher A (1957) Wirckung von Isopropyl-Isonikotinsäurehydrazid auf den Stoffwechsel von Catecholaminen und 5-Hydroxytryptamin im Gehirn. Schweiz Med Wochenschr 87:1532–1534PubMedGoogle Scholar
  12. 12.
    Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127:471PubMedCrossRefGoogle Scholar
  13. 13.
    Weil-Malherbe H, Bone AD (1958) Effect of reserpine on the intracellular distribution of catecholamines in the brain. Nature 181:1474–1475PubMedCrossRefGoogle Scholar
  14. 14.
    Bertler Å, Rosengren E (1959) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15:10–11PubMedCrossRefGoogle Scholar
  15. 15.
    Sano L, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in the human brain. Biochim Biophys Acta 32:586–587PubMedCrossRefGoogle Scholar
  16. 16.
    Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wschr 38:1236–1239PubMedCrossRefGoogle Scholar
  17. 17.
    Birkmayer W, Hornykiewicz O (1961) Der l-Dioxyphenylalanin (DOPA)–Effekt bei der Parkinson-Akinese. Wien Klin Wschr 73:787–788PubMedGoogle Scholar
  18. 18.
    Birkmayer W, Hornykiewicz O (1962) Der l-Dioxyphenylalanin-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiat Nervenkr 203:560–574PubMedCrossRefGoogle Scholar
  19. 19.
    Cotzias CC, Van Woert MH, Schiffer IM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374–379PubMedCrossRefGoogle Scholar
  20. 20.
    Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin and Dopamin in der Substantia nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 75:309–312PubMedGoogle Scholar
  21. 21.
    Dahlström A, Fuxe K (1964) Evidence far the existence of monoamine-containing neurons in the central nervous system. 1. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 62(Suppl 232):1–55Google Scholar
  22. 22.
    Poirier LJ, Sourkes TL (1964) Influance de locus niger sur la concentration des catecholamines du striatum. J Physiol (Paris) 56:426–427Google Scholar
  23. 23.
    Sourkes TL, Poirier LJ (1965) Influence of the substantia nigra on the concentration of 5-hydroxytryptarnine and dopamine of the striatum. Nature 207:202–203PubMedCrossRefGoogle Scholar
  24. 24.
    Denny-Brown D (1962) The basal ganglia and their relation to disorders of movement. Oxford University Press, OxfordGoogle Scholar
  25. 25.
    Mettler FA (1964) Substantia nigra and parkinsonism. Arch Neurol 11:529–542PubMedGoogle Scholar
  26. 26.
    Carpenter M (1966) Discussion in: Costa E, Cote LJ, Yahr MD (eds) Biochemistry and Pharmacology of the Basal Ganglia. Hewlett, Raven Press, p. 191Google Scholar
  27. 27.
    Hassler R (1967) Private communication to O. Hornykiewicz. Letter dated February 9, 1967Google Scholar
  28. 28.
    Seiden LS, Carlsson A (1964) Brain and heart catecholamine levels after l-dopa administration in reserpine treated mice: correlation with a conditioned avoidance response. Psychopharmacologia (Berl) 5:178–181CrossRefGoogle Scholar
  29. 29.
    Hanson LCF (1965) The disruption of conditioned avoidance response following selective depletion of brain catecholamines. Psychopharmacologia (Berl) 8:100–110CrossRefGoogle Scholar
  30. 30.
    Carlsson A (1965) Drugs which block the storage of 5-hydroxytryptamine and related amines. In: Eichler O, Farah A (eds) 5-Hydroxytryptamine and related indole alkylamines. Handbook of Experimental Pharmacology, vol 19 Springer, Heidelberg, p 529–592Google Scholar
  31. 31.
    Bertler Å, Rosengren E (1966) Possible role of brain dopamine. Pharmacol Rev 18:769–773PubMedGoogle Scholar
  32. 32.
    Vogt M (1973) Functional aspects of the role of catecholamines in the central nervous system. Br Med Bull 29:168–172PubMedGoogle Scholar
  33. 33.
    Jasper HH (1970) Neurophysiological mechanisms in parkinsonism. In: Barbeau A, McDowell FH (eds) l-dopa and Parkinsonism. FA Davies, Philadelphia, pp 406–411Google Scholar
  34. 34.
    Ward AA (1970) Physiological implications in the dyskinesias. In: Barbeau A, McDowell FH (eds) l-dopa and Parkinsonism. FA Davies, Philadelphia, pp 151–159Google Scholar
  35. 35.
    Moore RY (1970) The nigrostriatal pathway demonstrated by anterograde degeneration. In: Barbeau A, McDowell FH (eds) l-dopa and Parkinsonism. FA Davies, Philadelphia, pp 143–149Google Scholar
  36. 36.
    Lloyd K, Davidson L, Hornykiewicz O (1973) Metabolism of levodopa in the human brain. Adv Neurol 3:173–188Google Scholar
  37. 37.
    Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petric A (1974) Bromocriprine in parkinsonism. Br Med J 4:442–444PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Oleh Hornykiewicz
    • 1
  1. 1.Center for Brain Research, Medical University of ViennaViennaAustria

Personalised recommendations